[1] |
DOĞRUEL D, SERBES M, AŞ ŞAŞIHÜSEYINOĞLU, et al. Clinical and genetic profiles of patients with X-linked agammaglobulinemia from southeast Turkey: Novel mutations in BTK gene[J]. Allergol Immunopathol (Madr),2019,47(1):24-31.
|
[2] |
VU Q V, WADA T, LE H T, LE H T, et al. Clinical and mutational features of Vietnamese children with X-linked agammaglobulinemia[J]. BMC Pediatr, 2014,14:129.
doi: 10.1186/1471-2431-14-129
pmid: 24885015
|
[3] |
ALMONTASHERI A, AL-HUSAYNI F, ALSURAIHI A K, et al. The clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia[J]. Am J Case Rep, 2021, 22:e929447.
|
[4] |
YEH Y H, HSIEH M Y, LEE W I, et al. Distinct clinical features and novel mutations in taiwanese patients with X-linked agammaglobulinemia[J]. Front Immunol. 2020,11:2001.
|
[5] |
张抒扬. 罕见病诊疗指南2019年版[M].北京:人民卫生出版社,2019:768.
|
|
ZHANG S Y. Rare disease diagnosis and treatment guidelines 2019 Edition[M]. Beijing:People’s Medical Publishing House,2019:768.
|
[6] |
HERNANDEZ-TRUJILLO V, ZHOU C, SCALCHUNES C, et al. A registry study of 240 patients with X-linked agammaglobulinemia living in the USA[J]. J Clin Immunol,2023,43(6):1468-1477.
|
[7] |
BUCKLEY R H. Pulmonary complications of primary immunodeficiencies[J]. Paediatr Respir Rev,2004,5 ():S225-S233.
|
[8] |
SHILLITOE B, DUQUE J S R, Lai S H Y, et al. Outcomes of X-linked agammaglobulinaemia patients[J]. J Clin Immunol,2024,45(1):40.
doi: 10.1007/s10875-024-01829-z
pmid: 39541002
|
[9] |
O'TOOLE D, GROTH D, WRIGHT H, et al. X-Linked agammaglobulinemia:infection frequency and infection-related mortality in the USIDNET registry[J]. J Clin Immunol,2022,42(4):827-836.
|
[10] |
WEINBERGER T, FULEIHAN R, CUNNINGHAM-RUNDLES C, et al. Factors beyond lack of antibody govern pulmonary complications in primary antibody deficiency[J]. J Clin Immunol,2019,39(4):440-447.
doi: 10.1007/s10875-019-00640-5
pmid: 31089938
|
[11] |
CONLEY M E, NOTARANGELO L D, ETZIONI A. Diagnostic criteria for primary immunodeficiencies.Represen-ting PAGID(Pan-American Group for Immunodeficiency)and ESID(European Society for Immunodeficiencies)[J]. Clin Immunol,1999,93(3):190-197.
|
[12] |
RICHARDS S, AZIZ N, BALE S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med,2015,17(5):405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
[13] |
SHILLITOE B M J, GENNERY A R. An update on X-linked agammaglobulinaemia: clinical manifestations and management[J]. Curr Opin Allergy Clin Immunol,2019,19(6):571-577.
|
[14] |
中华医学会儿科学分会免疫学组,中华儿科杂志编辑委员会. 原发性免疫缺陷病免疫球蛋白G替代治疗专家共识[J]. 中华儿科杂志,2019,57(12):909-912.
|
|
The Subspecialty Group of Immunology, the Society of Pediatrics, Chinese Medical Association; the Editorial Board, Chinese Journal of Pediatrics. Expert consensus on immunoglobulin G replacement therapy in primary immunodeficiency disease[J]. Chin J Pediatr,2019,57(12):909-912.
|
[15] |
GRIGORIADOU S, CLUBBE R, GARCEZ T, et al. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy[J]. Clin Exp Immunol, 2022,210(1):1-13.
|
[16] |
MILITO C, PULVIRENTI F, CINETTO F, et al. Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies[J]. J Allergy Clin Immunol,2019,144(2):584-593.
doi: S0091-6749(19)30388-4
pmid: 30910492
|
[17] |
JUN L Z, GEN W, MIN X. Clinical efficacy and safety of allogeneic hematopoietic stem cell transplantation in treating X-linked agammaglobulinemia[C]. EBMT 51st Annual Meeting, 2025.
|